Deal Tracker · Regions

Latin America pharma licensing deals

4 licensing deals in Latin America tracked by EPT (2022–2026). Most active: Dongkook Pharmaceutical, Eurofarma, Faes Farma & Laboratorio Libra. Latest: Orchid Pharma → Laboratorio Libra (Licensing, 24 Oct 2026).

4
deals tracked
3
announced in 2026
$130.5m
disclosed value (2 deals)
100%
licensing, the top deal type
  • EPT has tracked 4 Latin America pharma licensing deals (2022–2026), 3 of them announced in 2026.
  • The countries that appear most often are Argentina (2), Brazil (2), Chile (2) & China (1).
  • Values were disclosed for 2 of 4 deals, totalling $130.5m; the largest is Orchid Pharma → Laboratorio Libra ($80m, 24 Oct 2026).

Countries involved

Argentina (2) · Brazil (2) · Chile (2) · China (1) · India (1) · Mexico (1)

Largest disclosed deals

Questions

How many Latin America pharma licensing deals has EPT tracked?
4 as of 24 Oct 2026, covering 2022–2026; 3 were announced in 2026. The most recent is Orchid Pharma → Laboratorio Libra (Licensing, 24 Oct 2026).
What is the largest disclosed Latin America pharma licensing deal?
Orchid Pharma → Laboratorio Libra: $80m (Licensing, 24 Oct 2026); Shanghai Henlius Biotech → Eurofarma: $50.5m (Licensing, 11 May 2022). Values are as announced by the parties.
Which countries appear most in Latin America pharma licensing deals?
Argentina (2), Brazil (2), Chile (2), China (1), India (1), Mexico (1) — counting where the parties are based and the markets the deals cover.

Browse deals

By region

GCC (83) · MENA (66) · Africa (17) · Latin America (17) · Southeast Asia (17) · Global (LMICs) (14) · CIS & Central Asia (13) · Türkiye (5) · Global ex-US (1)

By country

Saudi Arabia (69) · UAE (61) · China (31) · Egypt (27) · United States (26) · Oman (20) · India (19) · Switzerland (18) · Jordan (14) · South Korea (14) · Kazakhstan (13) · Algeria (12) · Türkiye (12) · United Kingdom (11) · Brazil (10) · Kuwait (10) · Iraq (8) · Morocco (8) · Bahrain (7) · Malaysia (7) · Spain (7) · Argentina (6) · Germany (6) · Indonesia (6) · Philippines (6) · Qatar (6) · Italy (5) · Mexico (5) · Vietnam (5) · France (4) · Taiwan (4) · Tunisia (4) · Canada (3) · Chile (3) · Denmark (3) · Greece (3) · Japan (3) · Lebanon (3) · Nigeria (3) · Pakistan (3) · South Africa (3) · Sweden (3) · Thailand (3) · Azerbaijan (2) · Colombia (2) · Ireland (2) · Kenya (2) · Libya (2) · Netherlands (2) · Singapore (2) · Uruguay (2) · Uzbekistan (2)

By year

2026 (193) · 2025 (27) · 2024 (6) · 2022 (3) · 2021 (2)

By therapeutic area

Multi-therapy (64) · Oncology (30) · Metabolic / Diabetes (27) · Cardiovascular (17) · Vaccines (15) · Immunology / Inflammation (13) · Rare / Orphan (9) · Infectious Disease (8) · CNS / Neurology (6) · Ophthalmology (6) · Consumer health (5) · Women's Health (4) · Respiratory (2)